Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

NCT01806597 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

205

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Palmoplantar Psoriasis

Interventions

BIOLOGICAL: secukinumab 150 mg
BIOLOGICAL: secukinumab 300 mg
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals